42 related articles for article (PubMed ID: 23902164)
1. A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease.
Mitsuyama K; Tomiyasu N; Suzuki A; Takaki K; Takedatsu H; Masuda J; Yamasaki H; Matsumoto S; Tsuruta O; Toyonaga A; Sata M
Clin Exp Immunol; 2006 Jan; 143(1):125-31. PubMed ID: 16367943
[TBL] [Abstract][Full Text] [Related]
2. IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer.
Wang L; Miyahira AK; Simons DL; Lu X; Chang AY; Wang C; Suni MA; Maino VC; Dirbas FM; Yim J; Waisman J; Lee PP
Cancer Res; 2017 Mar; 77(5):1119-1126. PubMed ID: 27879265
[TBL] [Abstract][Full Text] [Related]
3. Seed-derived peptide lunasin suppressed breast cancer cell growth by regulating inflammatory mediators, aromatase, and estrogen receptors.
Hsieh CC; Wu CH; Peng SH; Chang CH
Food Nutr Res; 2023; 67():. PubMed ID: 36794014
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6-derived cancer-associated fibroblasts activate STAT3 pathway contributing to gemcitabine resistance in cholangiocarcinoma.
Kittirat Y; Suksawat M; Thongchot S; Padthaisong S; Phetcharaburanin J; Wangwiwatsin A; Klanrit P; Sangkhamanon S; Titapun A; Loilome W; Saya H; Namwat N
Front Pharmacol; 2022; 13():897368. PubMed ID: 36091805
[TBL] [Abstract][Full Text] [Related]
5. IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment.
Manore SG; Doheny DL; Wong GL; Lo HW
Front Oncol; 2022; 12():866014. PubMed ID: 35371975
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Potential of Thymoquinone in Triple-Negative Breast Cancer Prevention and Progression through the Modulation of the Tumor Microenvironment.
Adinew GM; Taka E; Mochona B; Badisa RB; Mazzio EA; Elhag R; Soliman KFA
Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010954
[TBL] [Abstract][Full Text] [Related]
7. The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer.
Martínez-Pérez C; Kay C; Meehan J; Gray M; Dixon JM; Turnbull AK
J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834425
[TBL] [Abstract][Full Text] [Related]
8. Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse.
Manjili SH; Isbell M; Ghochaghi N; Perkinson T; Manjili MH
Semin Cancer Biol; 2022 Jan; 78():17-22. PubMed ID: 33785450
[TBL] [Abstract][Full Text] [Related]
9. The effect of marrow secretome and culture environment on the rate of metastatic breast cancer cell migration in two and three dimensions.
Curtis KJ; Mai C; Martin H; Oberman AG; Alderfer L; Romero-Moreno R; Walsh M; Mitros SF; Thomas SG; Dynako JA; Zimmer DI; McNamara LM; Littlepage LE; Niebur GL
Mol Biol Cell; 2021 May; 32(10):1009-1019. PubMed ID: 33689396
[TBL] [Abstract][Full Text] [Related]
10. GP130 Cytokines in Breast Cancer and Bone.
Omokehinde T; Johnson RW
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32023849
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 role in head and neck squamous cell carcinoma progression.
Choudhary MM; France TJ; Teknos TN; Kumar P
World J Otorhinolaryngol Head Neck Surg; 2016 Jun; 2(2):90-97. PubMed ID: 29204553
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine.
Vizoso FJ; Eiro N; Cid S; Schneider J; Perez-Fernandez R
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841158
[TBL] [Abstract][Full Text] [Related]
13. Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer.
Vaysse C; Lømo J; Garred Ø; Fjeldheim F; Lofteroed T; Schlichting E; McTiernan A; Frydenberg H; Husøy A; Lundgren S; Fagerland MW; Richardsen E; Wist EA; Muller C; Thune I
NPJ Breast Cancer; 2017; 3():19. PubMed ID: 28649659
[TBL] [Abstract][Full Text] [Related]
14. Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation.
Tvedt TH; Lie SA; Reikvam H; Rye KP; Lindås R; Gedde-Dahl T; Ahmed AB; Bruserud Ø
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27809289
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer.
Casneuf T; Axel AE; King P; Alvarez JD; Werbeck JL; Verhulst T; Verstraeten K; Hall BM; Sasser AK
Breast Cancer (Dove Med Press); 2016; 8():13-27. PubMed ID: 26893580
[TBL] [Abstract][Full Text] [Related]
16. Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer.
Heo TH; Wahler J; Suh N
Oncotarget; 2016 Mar; 7(13):15460-73. PubMed ID: 26840088
[TBL] [Abstract][Full Text] [Related]
17. Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells.
Eiró N; Sendon-Lago J; Seoane S; Bermúdez MA; Lamelas ML; Garcia-Caballero T; Schneider J; Perez-Fernandez R; Vizoso FJ
Oncotarget; 2014 Nov; 5(21):10692-708. PubMed ID: 25296979
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer.
Rego SL; Helms RS; Dréau D
Immunol Res; 2014 Jan; 58(1):87-100. PubMed ID: 24072428
[TBL] [Abstract][Full Text] [Related]
19. Soluble interleukin-6 receptor is a prognostic marker for relapse-free survival in estrogen receptor-positive breast cancer.
Won HS; Kim YA; Lee JS; Jeon EK; An HJ; Sun DS; Ko YH; Kim JS
Cancer Invest; 2013 Oct; 31(8):516-21. PubMed ID: 23902164
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
